Orthocell Limited (ASX:OCC), a Perth-based regenerative medicine company, has achieved its first commercial sales of Remplir — its collagen-based peripheral nerve reconstruction product — in Thailand. The milestone extends Remplir's commercial presence into a market the Company estimates at US$84 million in nerve repair opportunity, and follows Thai FDA approval and the appointment of MediTime as Orthocell's exclusive in-country distributor.

Thailand Market Entry and Distributor Partnership

MediTime, a specialist orthopaedics and sports medicine distributor, serves as Orthocell's exclusive in-country commercial partner for Remplir in Thailand. The distributor holds established coverage across leading hospitals, medical schools and regional centres, and has built a commercial presence in upper extremity orthopaedic surgery — the surgical specialty that forms Orthocell's core customer base of orthopaedic and plastic surgeons. MediTime's model is underpinned by surgeon education and key opinion leader relationships, which the Company considers supportive of both near-term adoption and longer-term market development.

Orthocell's Commercial Director for Asia Pacific, Hamish Thrum, is directly involved in the Thai launch preparations, working alongside MediTime to train sales representatives and build surgeon engagement at key centres. Managing Director Paul Anderson noted that while initial sales volumes are expected to be modest in the near term, the Company sees significant growth potential over the medium to longer term in the Thai market.

Remplir's Expanding Commercial Footprint

The Thai entry represents a continuation of Orthocell's systematic rollout of Remplir across Asian and global markets. Remplir is now approved for sale and generating Revenue in Australia, New Zealand, the United States, Canada, Singapore, Hong Kong and Thailand. The Company is also working toward EU and UK regulatory approval for Remplir, which is anticipated in the second half of CY2026 — a market the Company estimates at US$750 million in nerve repair opportunity, substantially larger than the Thai market.

Thailand's healthcare system is described by the Company as a strategically important market in Asia due to its sophisticated hospital infrastructure, well-developed surgical specialty ecosystem and significant medical tourism sector. These characteristics make it a meaningful reference market for Remplir adoption in the broader Asian region.

Financial Position

Orthocell reported available funds of A$44.1 million as at 30 June 2026 with no debt. This Capital position supports the Company's continued commercial expansion across markets, including the distributor development and surgeon education activities required to build Remplir adoption in new geographies. The availability of this capital without Debt obligations provides Orthocell with financial flexibility to sustain its commercialisation investments through the period of building market presence in each new geography.

Key Insights

Orthocell's first Thai commercial sales are a milestone in the sequential geographic rollout of Remplir, and the appointment of a well-connected specialty distributor in MediTime provides a commercially credible route to market in a country with meaningful nerve repair procedure volumes. The near-term revenue contribution from Thailand will be modest, as management itself acknowledged, but the entry validates the regulatory pathway and distributor model that Orthocell is replicating across Asian markets. The more commercially significant near-term catalyst remains the anticipated EU and UK regulatory approval in the second half of CY2026, given that market's estimated US$750 million scale is nearly ten times the size of the Thai market. Orthocell's A$44.1 million cash position, with no debt, provides the Balance Sheet runway to sustain its commercial build-out across multiple markets simultaneously.